What have we learned from long-term studies in juvenile idiopathic arthritis? – Prediction, classification, transition.

Table 2 Proportion of adults with juvenile idiopathic arthritis with physical disability and damage in long-term studies

Studies, country	n	Disease duration Years	Age at visit Years	CR^a %	Disability HAQ > 0 %	Damage
Studies, country	n	Disease duration Years	Age at visit Years	CR^a %	Disability HAQ > 0 %	JADI-A ≥ 1 %	JADI-E ≥ 1 %
Bertilsson, 2013, Sweden	86	17	n.a.	40^b	46	n.a.	n.a.
Selvaag, 2016, South-East Norway	176	30	39	59^c	45^d	n.a.	n.a
Dimopoulou, 2017, Greece	102 (302^e)	17	25	24 (47^e)	47 (30^e)	87	58
Minden, 2019, Germany	701	14	23	11	42	n.a.	n.a
Tollisen, 2019, South-East Norway	96	19	25	n.a.	46^f	n.a	n.a
Glerup, 2020, Nordic countries	434	18	24	33	28	20	13

CR clinical remission off medication, HAQ health assessment questionnaire (range 0–3) by self-report, JADI-A juvenile arthritis damage index– articular (range 0–72), JADI-E JADI– extraarticular (range 0–18) scored by the physician
^aAccording to the Wallace 2004 and/or ACR provisional criteria 2011 unless otherwise commented
^bEULAR definition of remission: Inactive disease off medication for ≥ 2 years
^cIncluding 69% assessed only by questionnaires (CR at 15-year follow-up and no history of flare assessed by questionnaire after 23 and 30 years)
^dAmong these, HAQ ≥ 0.5 (moderate to severe disability) = 25%
^eIncluding n = 205 lost to follow-up and assessed only by telephone interview
^fAmong these, HAQ ≥ 1.5 (severe disability) = 3%

ISSN: 1546-0096